Compound

Sanfetrinem

GlaxoSmithKline
Names
Sanfetrinem cilexetil, GV-104326
Chemical Class:
Trinem beta-lactam
Name of Target:
Bacterial cell wall
Description

Sanfetrinem cilexetil is the oral prodrug of sanfetrinem, a novel tricyclic β-lactam compound developed by GSK in the 1990s.  A Phase 2a clinical study is being planned for 1Q2021.

Developer Associations